ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,820Medicare Part D Prescriptions Filled, Including Refills

Rank: 196 out of 676

$504K Total Retail Price of All Prescriptions

Rank: 217 out of 676

446 Patients Receiving at Least One Drug in Part D
50%Patients 65 Years and Older
87% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Mississippi
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

48% of this provider’s 446 patients filled at least one prescription for a schedule three drug, compared to an average of 19%.

Risky Drugs to Seniors

2% of this provider’s 6,090 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$47 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 22.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Mississippi
HYDROCODONE-ACETAMINOPHEN 1,344 443 S3 1 1
FUROSEMIDE 421 291 2 4
LISINOPRIL 391 236 3 5
LOVASTATIN 245 148 4 33
DIOVAN 244 156 5 37
OMEPRAZOLE 228 122 6 2
POTASSIUM CHLORIDE 224 151 7 9
AMLODIPINE BESYLATE 217 146 8 3
DIOVAN HCT 199 178 9 41
HYDROCHLOROTHIAZIDE 189 102 10 12
ZOLPIDEM TARTRATE 183 64 11 21
LISINOPRIL-HYDROCHLOROTHIAZIDE 178 119 12 16
CYCLOBENZAPRINE HCL 175 12 R 13 50
METFORMIN HCL 171 113 14 8
MELOXICAM 168 100 15 13
AMLODIPINE BESYLATE-BENAZEPRIL 165 105 16 44
HYDRALAZINE HCL 145 98 17 77
GLIMEPIRIDE 131 109 18 30
CLONIDINE HCL 113 36 19 32
GABAPENTIN 112 52 20 10
CARVEDILOL 112 76 20 15
NIFEDIPINE ER 107 88 22 100
POLYETHYLENE GLYCOL 3350 106 76 23 56
METOPROLOL TARTRATE 101 55 24 22
SINGULAIR 100 57 25 80
FLUTICASONE PROPIONATE 97 43 26 49
ALLOPURINOL 92 60 27 31
PROAIR HFA 91 76 28 79
SIMVASTATIN 86 58 29 6
DONEPEZIL HCL 85 85 30 24
GLIPIZIDE 82 44 31 81
NASONEX 82 37 31 243
PLAVIX 81 67 33 40
NEXIUM 81 46 33 23
ATENOLOL 79 44 35 25
BENZTROPINE MESYLATE 79 38 R 35 129
CLOPIDOGREL 74 65 37 28
ATORVASTATIN CALCIUM 70 58 38 20
AMITRIPTYLINE HCL 70 13 R 38 46
GLYBURIDE 67 43 R 40 92
BYSTOLIC 64 39 41 96
VERAPAMIL ER 63 45 42 101
ACTOS 62 41 43 106
COLCRYS 62 20 43 122
RISPERIDONE 61 22 45 69
DIGOXIN 60 53 46 52
HALOPERIDOL 59 44 47 158
AZITHROMYCIN 56 18 48 39
TAMSULOSIN HCL 55 44 49 38
VENTOLIN HFA 50 16 50 127
TRAMADOL HCL 50 23 50 19
PAROXETINE HCL 50 15 50 65
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 10, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.